Valion Bio, Inc. Revenue
Valion Bio, Inc. (VBIO) reported Revenue of $86.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2025-08-14
- Valion Bio, Inc. revenues for the quarter ending 2025-06-30 was $86.00K, a 38.57% decline year-over-year.
- Valion Bio, Inc. revenues for the quarter ending 2025-03-31 was $70.00K, a 79.04% decline year-over-year.
- Valion Bio, Inc. revenues for the quarter ending 2024-12-31 was $180.00K, a 49.58% decline year-over-year.
- Valion Bio, Inc. revenues for the quarter ending 2024-09-30 was $126.00K, a 55.32% decline year-over-year.
- Valion Bio, Inc. revenues for fiscal 2024 was $780.00K, a 33.67% decline from fiscal 2023.
- Valion Bio, Inc. revenues for fiscal 2023 was $1.18M, a 36.09% decline from fiscal 2022.
- Valion Bio, Inc. revenues for fiscal 2022 was $1.84M, a 46.38% increase from fiscal 2021.
- Valion Bio, Inc. revenues for fiscal 2021 was $1.26M.
| Period end | Revenues 1 month | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|---|
| 2025-06-30 | $86.00K 10-Q · filed 2025-08-14 | $156.00K 10-Q · filed 2025-08-14 | $336.00K derived: sum of 3 quarters · filed 2025-08-14 | $462.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2025-03-31 | $70.00K 10-Q · filed 2025-05-15 | $250.00K derived: sum of 2 quarters · filed 2025-05-15 | $376.00K derived: sum of 3 quarters · filed 2025-05-15 | $516.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-12-31 | $180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $306.00K derived: sum of 2 quarters · filed 2025-03-21 | $446.00K derived: sum of 3 quarters · filed 2025-08-14 | $780.00K 10-K · filed 2025-03-21 | |
| 2024-09-30 | $126.00K 10-Q · filed 2024-11-14 | $266.00K derived: sum of 2 quarters · filed 2025-08-14 | $600.00K 10-Q · filed 2024-11-14 | $957.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-06-30 | $140.00K 10-Q · filed 2025-08-14 | $474.00K 10-Q · filed 2025-08-14 | $831.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.11M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $334.00K 10-Q · filed 2025-05-15 | $691.00K derived: sum of 2 quarters · filed 2025-05-15 | $973.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.13M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $639.00K derived: sum of 2 quarters · filed 2025-03-21 | $800.00K derived: sum of 3 quarters · filed 2025-03-21 | $1.18M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $282.00K 10-Q · filed 2024-11-14 | $443.00K derived: sum of 2 quarters · filed 2024-11-14 | $819.00K 10-Q · filed 2024-11-14 | $1.23M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $161.00K 10-Q · filed 2024-08-14 | $537.00K 10-Q · filed 2024-08-14 | $945.00K derived: sum of 3 quarters · filed 2024-08-14 | $1.42M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $376.00K 10-Q · filed 2024-05-15 | $784.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.26M derived: sum of 3 quarters · filed 2024-05-15 | $1.79M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $408.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $885.00K derived: sum of 2 quarters · filed 2024-03-25 | $1.41M derived: sum of 3 quarters · filed 2024-03-25 | $1.84M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $477.00K 10-Q · filed 2023-11-14 | $1.00M derived: sum of 2 quarters · filed 2023-11-14 | $1.43M 10-Q · filed 2023-11-14 | $1.82M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $528.00K 10-Q · filed 2023-08-14 | $956.00K 10-Q · filed 2023-08-14 | $1.34M derived: sum of 3 quarters · filed 2023-08-14 | $1.62M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $428.00K 10-Q · filed 2023-05-15 | $817.00K derived: sum of 2 quarters · filed 2023-05-15 | $1.09M derived: sum of 3 quarters · filed 2023-05-15 | $1.36M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2022-01-31 | $428.00K 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | $389.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $666.00K derived: sum of 2 quarters · filed 2023-03-31 | $934.00K derived: sum of 3 quarters · filed 2023-03-31 | $1.26M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $277.00K 10-Q · filed 2022-11-14 | $545.00K derived: sum of 2 quarters · filed 2022-11-14 | $868.00K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $268.00K 10-Q · filed 2022-08-15 | $591.00K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $323.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |